USFDA9 Sept 2025, 08:37 pm
Sun Pharma's Halol Facility Classified as 'Official Action Indicated' by US FDA
AI Summary
Sun Pharmaceutical Industries Ltd. has announced that the US Food and Drug Administration (FDA) has classified its Halol Facility as 'Official Action Indicated' (OAI). This classification means that the facility is not fully compliant with certain current good manufacturing practices (CGMP) as per FDA standards. The Halol facility is currently under Import Alert, which means that shipments from the facility to the US are being refused, with certain exemptions for drug shortage situations. Sun Pharma remains committed to working with the FDA and maintaining CGMP standards at all its facilities to provide high-quality medicines globally.
Key Highlights
- Sun Pharma's Halol Facility classified as 'Official Action Indicated' by US FDA
- Facility not fully compliant with certain CGMP standards as per FDA
- Halol facility under Import Alert, refusing shipments to US
- Exemptions for drug shortage situations
- Sun Pharma committed to working with FDA and maintaining CGMP standards